Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults.
Expert opinion on drug metabolism & toxicology · 2022-03-01 · Other / unclear
Abstract
INTRODUCTION: The administration of the opioid antagonist naloxone in the community is a measure to prevent death from opioid overdose. Approved nasal naloxone sprays deliver initial doses of 0.9 to 8 mg. The level of the initial community dose is controversial, as the scientific base is weak.In this review knowledge of the pharmacokinetics of nasal, both approved and improvised nasal sprays, and intramuscular naloxone will be utilized to evaluate dose-effect relationships in previous studies of opioid overdose outcomes. AREAS COVERED: The aim was to present scientifically based considerations on the initial nasal naloxone doses currently available, which reasonably balances the effect and adverse outcomes, given that at least two doses are at hand. Also included in these considerations is the challenge by illicitly manufactured fentanyl and analogs.This paper is based on both peer-reviewed and grey literature identified by several searches, of such as naloxone pharmacokinetics/formulations/outcomes/emergency medical services, in PubMed and Embase. EXPERT OPINION: There is little scientific evidence that supports the use of initial systemic dosing that exceeds 0.8 mg in the community. Higher doses increase the risk of withdrawal symptoms feared in people who use opioids. Many obstacles may reduce the potential of community-administered naloxone.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Poisoning & substance use · Intranasal administration · Antidotes · Synthetic opioids · Naloxone
Related articles
- Trends and characteristics during 17 years of naloxone distribution and administration through an overdose prevention program in Pittsburgh, Pennsylvania. (PLoS One, 2025)
- High-dose naloxone formulations are not as essential as we thought. (Harm Reduct J, 2024)
- Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021. (Drug Alcohol Depend, 2024)
- An Emerging Synthetic Opioid in the Drug Supply: A Case of Opioid Overdose with Biological Confirmation of Cychlorphine. (J Med Toxicol, 2026)
- American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time. (Clin Toxicol (Phila), 2023)
- Prehospital Naloxone Administration Patterns during the Era of Synthetic Opioids. (Prehosp Emerg Care, 2024)